This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Love, C.D.B. Articles by Dixon, J. M. Search for Related Content PubMed PubMed Citation Articles by Love, C.D.B. Articles by Dixon, J. M. Social Bookmarking                            What's this?

Investigation of Endometrial Abnormalities in Asymptomatic Women Treated With Tamoxifen and an Evaluation of the Role of Endometrial Screening

From the Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom.

Address reprint requests to C.D.B. Love, MBChB, Academic Office, Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom; email jmd{at}wght.demon.co.uk

PURPOSE: Tamoxifen is the most commonly prescribed adjuvant therapy for women with breast cancer. It has agonist activity on the endometrium and is associated with an increased risk of endometrial cancer. The aim of this study was to evaluate whether screening with transvaginal ultrasound (TV USS) with or without hysteroscopy is worthwhile.

PATIENTS AND METHODS: A total of 487 women with breast cancer, 357 treated with tamoxifen and 130 controls, were screened with TV USS, and endometrial thickness was measured. Women with thickened endometrium underwent outpatient hysteroscopy.

RESULTS: Length of time on tamoxifen ranged from 5 to 191 months (mean, 66 months), and endometrial thickness ranged from 1 to 38 mm (mean, 7.3 mm). Women treated with tamoxifen had significantly thicker endometrium than did controls (P < .0001). There was a statistically significant (P < .0001) positive correlation between length of time on tamoxifen and endometrial thickness. One hundred forty-five women had endometrium greater than 5 mm on USS, and 134 underwent successful outpatient hysteroscopy, 61 of whom had atrophic endometrium, resulting in a 46% false-positive scan rate. The remaining women all had benign features to explain the USS findings.

CONCLUSION: TV USS detects a high incidence (41%) of apparent endometrial thickening in women treated with tamoxifen, although 46% had atrophic endometrium on further assessment, and none of the remaining asymptomatic women had significant lesions. Length of time on tamoxifen relates to endometrial thickening as measured by TV USS. TV USS is a poor screening tool because of the high false-positive rate. The low frequency of significant findings suggests that endometrial screening in asymptomatic women is not worthwhile.

Financial support to purchase the transvaginal probe was provided by the Sarah Percy Research Fund of the Edinburgh Breast Unit.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Bertelli, E. Hall, E. Ireland, C. F. Snowdon, J. Jassem, K. Drosik, H. Karnicka-Mlodkowska, R. C. Coombes, and J. M. Bliss Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen Ann. Onc., August 28, 2009; (2009) mdp358v1. [Abstract] [Full Text] [PDF]

				F. Montemurro, M. Aglietta, and L. Del Mastro Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2566 - 2567. [Full Text] [PDF]

				M. Fishman, M. Boda, E. Sheiner, J. Rotmensch, and J. Abramowicz Changes in the Sonographic Appearance of the Uterus After Discontinuation of Tamoxifen Therapy J. Ultrasound Med., April 1, 2006; 25(4): 469 - 473. [Abstract] [Full Text] [PDF]

				J Weaver, J M McHugo, and T J Clark Accuracy of transvaginal ultrasound in diagnosing endometrial pathology in women with post-menopausal bleeding on tamoxifen Br. J. Radiol., May 1, 2005; 78(929): 394 - 397. [Abstract] [Full Text] [PDF]

				C. Buijs, P.H.B. Willemse, D.J. Tinga, H. Hollema, E.G. de Vries, and M.J.E. Mourits Side Effects of Therapy: CASE 2. Tamoxifen and Uterine Abnormalities J. Clin. Oncol., June 15, 2004; 22(12): 2505 - 2507. [Full Text] [PDF]

				K. Fong, P. Causer, M. Atri, A. Lytwyn, and R. Kung Transvaginal US and Hysterosonography in Postmenopausal Women with Breast Cancer Receiving Tamoxifen: Correlation with Hysteroscopy and Pathologic Study RadioGraphics, January 1, 2003; 23(1): 137 - 150. [Abstract] [Full Text] [PDF]

				M J E Mourits, K A T. Hoor, A G J van der Zee, P H B Willemse, E G E de Vries, and H Hollema The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium J. Clin. Pathol., July 1, 2002; 55(7): 514 - 519. [Abstract] [Full Text] [PDF]

				V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]

				K. Fong, R. Kung, A. Lytwyn, M. Trudeau, W. Chapman, P. Nugent, P. Glanc, L. Manchul, D. Szabunio, and T. Myhr Endometrial Evaluation with Transvaginal US and Hysterosonography in Asymptomatic Postmenopausal Women with Breast Cancer Receiving Tamoxifen Radiology, September 1, 2001; 220(3): 765 - 773. [Abstract] [Full Text] [PDF]

				R. A. Smith, A. C. von Eschenbach, R. Wender, B. Levin, T. Byers, D. Rothenberger, D. Brooks, W. Creasman, C. Cohen, C. Runowicz, et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection CA Cancer J Clin, January 1, 2001; 51(1): 38 - 75. [Abstract] [Full Text] [PDF]

				C. D. Runowicz Gynecologic Surveillance of Women on Tamoxifen: First Do No Harm J. Clin. Oncol., October 20, 2000; 18(20): 3457 - 3458. [Full Text] [PDF]

				R. R. Barakat, T. A. Gilewski, L. Almadrones, P. E. Saigo, E. Venkatraman, C. Hudis, and W. J. Hoskins Effect of Adjuvant Tamoxifen on the Endometrium in Women With Breast Cancer: A Prospective Study Using Office Endometrial Biopsy J. Clin. Oncol., October 20, 2000; 18(20): 3459 - 3463. [Abstract] [Full Text] [PDF]

				B. Gerber, A. Krause, H. Muller, T. Reimer, T. Kulz, J. Makovitzky, G. Kundt, and K. Friese Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound J. Clin. Oncol., October 20, 2000; 18(20): 3464 - 3470. [Abstract] [Full Text] [PDF]

				M. J. Mourits, P. H. Willemse, E. G. de Vries, A. G. van der Zee, C. D. B. Love, J. M. Dixon, and R. R. Barakat Tamoxifen and Endometrial Screening J. Clin. Oncol., January 14, 2000; 18(2): 446 - 446. [Full Text]

				R. R. Barakat Screening for Endometrial Cancer in the Patient Receiving Tamoxifen for Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 1967 - 1967. [Full Text] [PDF]